Please login to the form below

Not currently logged in
Email:
Password:

Ludwig Hantson

This page shows the latest Ludwig Hantson news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy

According to Alexion chief executive Ludwig Hantson, SYNT001 is “the first, and currently the only, anti-FcRn therapy in clinical development” and has shown proof-of-concept as a way to ... The acquisition of Syntimmune "represents a critical step in

Latest news

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    Ludwig Hantson, Alexion’s chief executive, said: “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial focus on metabolic

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Nevertheless, Baxalta chief executive Ludwig Hantson - who had dismissed Shire's initial overture saying there was little overlap between the companies and that rare disease therapies "require focus" - has now warmed

  • Baxalta spells out opposition to Shire Baxalta spells out opposition to Shire

    Firm has rejected unsolicited $30bn bid from the Irish biopharma. Baxalta chief executive Ludwig Hantson said yesterday that Shire's $30bn takeover bid was a "puzzling" approach that would short-change ... Hantson insisted Shire's $45-per-share offer is

  • Shire makes shock $30bn bid for Baxalta Shire makes shock $30bn bid for Baxalta

    Yesterday Shire's CEO Flemming Ornskov wrote to the recently appointed chief at Baxalta, Ludwig Hantson, saying: “Your lack of engagement has been surprising. ... The specialist in haematology, immunology and cancer therapies has "a solid foundation

  • Baxalta will add $2.5bn in new product turnover by 2020 Baxalta will add $2.5bn in new product turnover by 2020

    The specialist in haematology, immunology and cancer therapies has "a solid foundation and strong momentum," according to Baxter's chief executive-elect Ludwig Hantson, who is due to take charge when

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics